

Data	Presenter	Title	Journal	Year	Vol	Page
2022/4/5	西村	Positron Emission tomography-Driven Strategy in Advanced Hodgkin Lymphoma:Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Positron Emission tomography-Driven Strategy in Advanced Hodgkin Lymphoma:Prolonged Follow-Up of the AHL2011 Phase III Lymphoma Study Association Study	J Clin Oncol.	2022	40(10)	1091-1101
	加藤	Autologous transplant vs chimeric antigen receptor-T-Cell therapy for relapsed DLBCL in partial remission	Blood	2022	139(9)	1330-1339
2022/4/12	勝岡	Gain of function mutation in RPA1 cause a syndrome with short telomeres and somatic genetic rescue	Blood	2022	139(7)	1039-1051
	今泉	Phase 1 /dose expansion trial of brentuximab vedotin and lenalidomide in relapse or refractory diffuse large B-cell lymphoma	Blood	2022	139(13)	1999-2010
2022/4/19	クリクラ学生	Magnesium sensing via LFA-1 regulates CD8+ T cell effector function	Cell	2022	185(4)	585-602
	安東	The day 100 score predicts moderate to severe cGVHD, transplant mortality, and survival after hematopoietic cell transplantation	Blood Adv	2022	6(7)	2309-2318
2022/4/26	山田	PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma	Blood	2016	128(10)	1374-1381
	糸永	YBX1 mediates translation of oncogenic transcripts to control cell competition in AML	Leukemia	2022	36(2)	426-437
2022/5/10	蓬菜	Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia	N Eng J Med	2022	386(16)	1519-1531
	佐藤	Idecabtagene Vicleucef in Relapsed and Refractory Multiple Myeloma	N Eng J Med	2022	384(3)	705-716
2022/5/17	一瀬	Analysis of distinct SF3B1 hotspot mutations in relation to clinical phenotypes and response to study myeloid neoplasia	Leuk Lymphoma	2021	62(3)	735-738
	宮崎	TRAF6 functions as a tumor suppressor in myeloid malignancy by directly targeting MYC oncogenic activity	Cell stem cell	2022	29(2)	298-314
2022/5/24	クリクラ学生	Venetoclax and Hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukemia	Br J Haematol	2022	196(6)	e71-e74
	長井	Immune responses against SARS-CoV2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study	Nat Cancer	2022	3(5)	552-564
2022/5/31	古本	第62回リンパ・網内系学会 予行演習				
	加藤	Axicabtagene cicleucef as first-line therapy in high-risk large B cell lymphoma :the phase 2 ZUMA-12 trial	Nat Med	2022	28(4)	735-742
2022/6/1	勝岡	Measurable residual disease monitoring provides insufficient lead-time to prevent morphological relapse in the majority of patients with core-binding factor acute myeloid leukemia.	Haematologica	2021	106(1)	56-63
	今泉	The CLL12 trial :ibrutinib vs placebo in treatment-naive , early-stage chronic lymphocytic leukemia.	Blood	2022	139(2)	177-187
2022/6/14	西村	Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk	J Clin Oncol.	2022	40(25)	2889-2900
	安東	Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	Cancer Cell	2022	40(5)	494-508
2022/6/21	松本	Obinutuzumab plus lenalidomide in advanced, previously untreated follicular lymphoma in need of systemic therapy: a LYSA study	Blood	2022	139(15)	2338-2346
	糸永	Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics, and DNA repair	Blood	2022	139(23)	3418-3429
2022/6/28	一瀬	R-loop proximity proteomics identifies a role of DDX41 in transcription-associated genomic instability	Nat Commun	2021	12(1)	7314
	佐藤	Superior Efficacy of Midostaurin Over Cladribine in Advanced Systemic Mastocytosis: A Registry-Based Analysis	J Clin Oncol.	2022	40(16)	1783-1794